One of the biggest challenges in oncology is the development of drug resistance, where tumor cells eventually "learn" to pump out toxins or stop expressing the target antigen. However, new research featured in the Antibody Drug Conjugate Market analysis suggests that newer ADCs are being designed with a "bystander effect." This allows the drug to kill neighboring cancer cells even if they don't...
Deutsch 
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt